Clinical Profile of Neonates Having Patent Ductus Arteriosus

Learn more about:
Related Clinical Trial
Clinical Profile of Neonates Having Patent Ductus Arteriosus Prophylactic Treatment of the Ductus Arteriosus in Preterm Infants by Acetaminophen Aminoglycosides and Duct Radiation-Free Heart Catheterization Using MRI Hemodynamic Responses to Cardio-respiratory Events in Preterm Infants Paracetamol (Acetaminophen) for Closure of PDA in Preterm Infants Impact of Maternal-infant Therapeutics on Safety, Mortality, and Disability The Pharmacology and Hemodynamics of Dexmedetomidine in Children With Congenital Heart Disease The Preterm Infants’ Paracetamol Study Fenoldopam to Prevent Renal Dysfunction in Indomethacin Treated Preterm Infants Curosurf and Survanta Treatment(CAST)of RDS in Very Premature Infants Evaluation of the Brain and Renal Regional Oxygenation Using NIRS in Preterm Infants Feasibility, Efficacy and Safety of IBS ® for Implantaiton in the PDA in Duct-dependent Cyanotic CHD Hyperion™ International Registry Trial NIRS in PDA VLBW Infants Amplatzer Piccolo Occluder Japan Post-marketing Database Surveillance Comparison of Oral and Intravenous Ibuprofen for PDA Treatment in Premature Infants The Impact of Platelet Functions on Spontaneous Ductal Closure in Preterm Infants Lifetech CeraFlex™ Post-Market Surveillance Study Treatment of a PDA With Acetaminophen in Preterm Neonates: Exploring Various Indications Nit-Occlud PDA Post-Approval Study Ibuprofen and Renal Function in Premature Infants A New Device for Measuring of Lung Photoplethysmography and Pulmonic Arterial Saturation Canadian National PDA Treatment Study Long Term Results of 450 Percutaneous Closures of PDA in a Single Center Efficacy and Safety of Oral Versus Intravenous Ibuprofen for PDA Treatment in ELBW Infants AMPLATZER Duct Occluder II Additional Sizes A NEW SCORING SYSTEM FOR PREDICTION OF PDA Clinical Trial to Evaluate Two Guidelines for the Administration of Ibuprofen in the Treatment of Persistent Ductus Arteriosus Eco-guided: Impact in the Intestinal Prognosis Feeding During Ibuprofen or Indomethacin Treatment of Preterm Infants The Efficacy of Implementing a Treatment Algorithm in Managing Patent Ductus Arteriosus (PDA) in the Extremely Low Birth Weight Neonatal Population. Safety and Efficacy of Ibuprofen in Term Newborns With Patent Ductus Arteriosus (PDA) Ibuprofen vs. Continuous Indomethacin in the Treatment of PDA Addition of Acetaminophen in Standard PDA Management Second Course of Therapy for Resistant Patent Ductus Arteriosus (PDA) Safety/Efficacy Study of Optimizing Ibuprofen Dosing to Achieve Higher PDA Closure Rates Paracetamol Versus Ibuprofen for PDA Closure Population Pharmacokinetics and Dosage Individualization of Paracetamol and Ibuprofen in Children With PDA Timing for the Medical Treatment of Patent Ductus Arteriosus in Preterm Infants Early Treatment Versus Expectative Management of PDA in Preterm Infants International Experience in Timing And Choices for Ductal Closure in Patent Ductus Arteriosus:INTERPDA Trial Comparative Study of Efficacy and Safety of Oral Ibuprofen and Intravenous Ibuprofen in Closure of Patent Ductus Arteriosus in Very Low Birth Weight Infants Do Elevated BNP Levels Predict Hemodynamically Significant PDAs The Use of B-type Natriuretic Peptide (BNP) to Predict Closure of a Patent Ductus Arteriosus (PDA) in Premature Infants Brain, Gut and Kidney Blood Flow During Medical Closure of PDA Early Treatment Versus Delayed Conservative Treatment of the Patent Ductus Arteriosus Serum Level Measurement of Oral Paracetamol and Oral Ibuprofen for Patent Ductus Arteriosus Treatment in Preterm Infants The Role of Fetal Ductus Arteriosus in Predicting Spontaneous Labour at Term AMPLATZER Duct Occluder II Clinical Study The Role of Fetal Ductus Arteriosus in Predicting Spontaneous Preterm Birth Paracetamol and Patent Ductus Arteriosus (PDA) Comparison of 2 Different Indomethacin Dosing Protocols to Treat Infants Delivered at Near Infrared Spectroscopy to Determine Patent Ductus Arteriosus Closure Early Prediction of Spontaneous Patent Ductus Arteriosus (PDA) Closure and PDA-Associated Outcomes Oral Paracetamol Versus Oral Ibuprofen in Management of Patent Ductus Arteriosus in Preterm Infants: A Randomised Controlled Trial Early Versus Late Use of Ibuprofen for Patent Ductus Arteriosus (PDA) Closure Pocket Echocardiography System (PES) for Detection of PDA in Neonates Treating the Resistant Patent Ductus Arteriosus (PDA) Echocardiographically Guided Versus Standard Ibuprofen Treatment for Patent Ductus Arteriosus IV Acetaminophen and Patent Ductus Arteriosus Closure Of Patent Ductus Arteriosus With the AMPLATZER Duct Occluder the AMPLATZER® Duct Occluder Closure of Patent Ductus Arteriosus With Indomethacin or Ibuprofen in Extreme Low Birth Weight Infants Platelet Transfusion for Treatment of Patent Ductus Arteriosus in Thrombocytopenic Preterm Neonates Nitric Oxide, Endothelin-1, and the Patency of Ductus Arteriosus in Preterm Infants Early Ibuprofen Treatment of Patent Ductus Arteriosus (PDA) in Premature Infants (TRIOCAPI) Influence of Treatment for Patent Ductus Arteriosus on Cerebral Oxygenation in Preterm Infants An Escalating Dose Indomethacin for the Treatment of Persistent Patent Ductus Arteriosus (PDA) In Preterm Infants Patent Ductus Arteriosus and Splanchnic Oxygenation at First Feed Preliminary Percutaneous Intervention Versus Observational Trial of Arterial Ductus in Low-weight Infants Non-Invasive Detection of Tissue Oxygen Deprivation in Premature Infants With Patent Ductus Arteriosus. Safety and Effectiveness Study With a New PDA Occluder for Closure of Patent Ductus Arteriosus

Brief Title

Clinical Profile of Neonates Having Patent Ductus Arteriosus

Official Title

Clinical Profile of Neonates Diagnosed by Echocardiography as Having Patent Ductus Arteriousus in Assiut University Hospital for Children

Brief Summary

      The study aims to evaluate the clinical presentation and course of PDA diagnosed at neonatal
      period in the neonatology unit of Assiut University Hospital for Children.

Detailed Description

      One of the most common cardiovascular problems that prematurely born infants experience early
      in life is patent ductus arteriosus (PDA).

      The ductus arteriosus is a blood vessel that connects the two major arteries, namely the
      aorta and the pulmonary artery, and is essential in maintaining circulation in fetal life.
      After the baby is born and the fetal circulation changes to adult circulation, the ductus
      arteriosus functionally closes between 18 and 24 hours of life (1 ).

      The arterial duct is a fetal blood vessel that is programmed to close shortly after birth. If
      the vessel remains patent beyond 3 months of life (a persistently patent arterial duct) it
      can result in volume loading of the left heart and should be closed either surgically or by a
      catheter-based procedure. A patent arterial duct is common in the newborn, particularly
      premature infants, and can contribute to persistent respiratory problems. (2) Historical
      estimates have placed the incidence of isolated PDA at approximately 0.05% of all live
      births. Isolated PDA accounts for 5% to 10% of congenital heart defects (3) number most
      likely represents the prevalence of a "symptomatic" PDA-that is, one that results in evidence
      of increased pulmonary blood flow, left heart volume overload, elevated PA pressure, murmur,
      etc. With the advent of color Doppler echocardiography, the incidental recognition of
      asymptomatic "silent" ductus has become more common. Some have estimated the prevalence of
      silent PDA among children and adults to be up to 0.5%, far more common than the "symptomatic"
      PDA (4).

      However, in babies born prematurely, the ductus arteriosus often fails to close spontaneously
      and leads to a number of morbidities. it has been shown that in infants born with a birth
      weight of <1000 g, the ductus arteriosus remains open in 66% of infants beyond the first week
      of life. In the extreme premature population born at 24 weeks of gestation, only 13% of
      infants are found to have their ductus closed by the end of the first week (5).This makes PDA
      an important issue from the clinical management perspective in the first few days of life in
      preterm infants.

      It is associated with a number of comorbidities such as necrotising enterocolitis (NEC),
      bronchopulmonary dysplasia and intraventricular haemorrhage (IVH) (6-7).

      The management controversy has mainly focused on when to treat and with what to treat. To
      increase the complexity of m atters, these two aspects of PDA management are not mutually
      exclusive, with the modality of treatment often being dictated by the timing of treatment.
      There have been a large number of published studies, meta-analyses and editorials focusing on
      different aspects of management.(8-9)Regarding the timing of treatment, prophylactic therapy
      has gradually fallen out of favor and neonatal units have shifted towards a more conservative
      approach by treating only the clinically and echocardiographically (ECHO) significant PDA
      (10).However, the big dilemma that still persists among neonatologists is what to use as the
      primary modality of treatment.

Study Type


Primary Outcome

Determine the percentage of cases with PDA admitted to our neonatology unit per year.


Patent Ductus Arteriosus




* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

April 1, 2021

Completion Date

February 2022

Primary Completion Date

January 1, 2022

Eligibility Criteria

        Inclusion Criteria:

        - 1- Neonatal period (0-28 days) including fullterm and preterm infants for whom
        echocardiography is indicated.

        2- Absence of other congenital cardiac defects.

        Exclusion Criteria:

          -  PDA associated with other cardiac anomalies.




N/A - 28 Days


, 01016940909, [email protected]

Administrative Informations



Organization ID

PDA in neonatology

Responsible Party

Principal Investigator

Study Sponsor

Assiut University

Study Sponsor

, , 

Verification Date

December 2020